Associated Papers
Detection Mutations of JAK2 exon 12 in Patients with JAK2 (V617F)-negative Myeloproliferative Disorders.
Makani SZ et al.
The Gulf Journal of Oncology, 2017
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Wu Z et al.
Journal of Hematology & Oncology, 2014
Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
Gong JZ et al.
The Journal of Molecular Diagnostics : Jmd, 2013
The JAK2 exon 12 mutations: a comprehensive review.
Scott LM
American Journal of Hematology, 2011
Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.
Jatiani SS et al.
Genes & Cancer, 2010
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.
Olcaydu D et al.
Leukemia, 2009
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Schnittger S et al.
Haematologica, 2009
JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH et al.
Cancer Genetics and Cytogenetics, 2009
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Walz C et al.
Leukemia, 2008
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
Pietra D et al.
Blood, 2008
Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis.
Cazzola M
Haematologica, 2007
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.
de Freitas RM et al.
Revista Brasileira De Hematologia E Hemoterapia, 0
Select a paper to view details